SDGR | Ticker Profile - Titan Protect

SDGR

Schrödinger, Inc.

Healthcare · Health Information Services · NMS

$14.38

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$989M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-8.46

Based on estimated future earnings — lower means cheaper

Rev Growth

-1.6%

Year-over-year revenue change

Profit Margin

-40.6%

How much profit the company keeps from each dollar of revenue

ROE

-30.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.00

+39% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About Schrödinger, Inc.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

https://www.schrodinger.com

Country: United States Employees: 850 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

-0.057

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0086

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.321

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-18.8%

Historical annualised return based on price data

Max Drawdown

-58.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.58

Significantly more volatile than the market

52W High

$27.63

48% below the year high

52W Low

$10.95

31% above the year low

Avg Volume

1,305,872

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

24.5%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.40

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

34.13

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.74

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.64

Like current ratio but excludes inventory — stricter test

Gross Margin

55.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-83.3%

Profit from core operations before interest and tax

Free Cash Flow

$-49,420,624

Negative — the business is spending more than it generates

Revenue (TTM)

$255M

Total revenue over the last 12 months

Net Income

$-103,483,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$30.00

Target Median

$20.00

Target Low

$13.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go